In the fast evolving area of oncology study, exact and successful mutation screening is critical for establishing specific therapies. The KRAS Services Platform plays a pivotal part in this landscape by giving in depth methods for KRAS mutation profiling and Evaluation. KRAS mutations, present in close to 95% of RAS-related oncogenic alterations, a